BACKGROUND: This survey aim was to evaluate the epidemiology and outcomes of neuroblastoma patients in one the most important children referral hospitals in Iran as a model from developing countries. MATERIALS AND METHODS: This retrospective, non-randomized analytic study was conducted on 219 newly diagnosed neuroblastoma cases. RESULTS: The age of patients ranged from 1-156 months with the average of 40.5±2.44, with a male/female ratio of 1.9/1. Of the total, 172 (78.5%) were children and 47 (21.5%) were infants The adrenals were the most common primary site (60%). Stage 4 at diagnosis accounted for about 54% of all enrolled patients. Infants had significantly better cumulative survival (85±8%) than children (33±7%) during the follow up period and the survival rate improved from 33±7% in 1974-1994 to 58±9% in 1995-2005. CONCLUSIONS: This study indicates that our patient population with neuroblastomas tends to have more advanced disease, perhaps with poor biologic markers, but our analysis shows that the outcomes have improved over 32 years although the overall survival of Iranian neuroblastoma patients is still lower than developed countries. Late diagnosis, inability to determine risk group during the years of study and using single protocol for all enrolled patients can be the reasons of lower survival rate.
BACKGROUND: This survey aim was to evaluate the epidemiology and outcomes of neuroblastomapatients in one the most important children referral hospitals in Iran as a model from developing countries. MATERIALS AND METHODS: This retrospective, non-randomized analytic study was conducted on 219 newly diagnosed neuroblastoma cases. RESULTS: The age of patients ranged from 1-156 months with the average of 40.5±2.44, with a male/female ratio of 1.9/1. Of the total, 172 (78.5%) were children and 47 (21.5%) were infants The adrenals were the most common primary site (60%). Stage 4 at diagnosis accounted for about 54% of all enrolled patients. Infants had significantly better cumulative survival (85±8%) than children (33±7%) during the follow up period and the survival rate improved from 33±7% in 1974-1994 to 58±9% in 1995-2005. CONCLUSIONS: This study indicates that our patient population with neuroblastomas tends to have more advanced disease, perhaps with poor biologic markers, but our analysis shows that the outcomes have improved over 32 years although the overall survival of Iranian neuroblastomapatients is still lower than developed countries. Late diagnosis, inability to determine risk group during the years of study and using single protocol for all enrolled patients can be the reasons of lower survival rate.
Authors: Abeer Al-Battashi; Ameera Al-Rahbi; Abdulhakeem Al-Rawahi; Mohammed Mamdouh; Ibrahim Al-Ghaithi; Fatma A Ramadhan Journal: Sultan Qaboos Univ Med J Date: 2021-11-25